Autonomix Medical, Inc.

Equities

AMIX

US05330T1060

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
0.96 ^USD	-4.95%		-8.57%	0.00%

06-18	Autonomix Medical, Inc. Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial	CI
06-17	Autonomix Medical, Inc. Announces Chief Executive Officer Changes	CI

Autonomix Medical, Inc. to Announce Preliminary Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial on June 18, 2024

June 10, 2024 at 01:00 pm

Autonomix Medical, Inc. announced it will release preliminary results from the first five "lead-in" patients in the Company's ongoing proof-of-concept (PoC) human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic reserves and mitigate pain in patients with pancreatic cancer pain on June 18, 2024.

Latest news about Autonomix Medical, Inc.

Autonomix Medical, Inc. Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial	06-18	CI
Autonomix Medical, Inc. Announces Chief Executive Officer Changes	06-17	CI
Autonomix Medical, Inc. Announces Executive and Board Changes	06-17	CI
Autonomix Medical, Inc. to Announce Preliminary Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial on June 18, 2024	06-10	CI
Autonomix Medical, Inc. Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial	06-03	CI
Autonomix Medical, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	05-31	CI
Autonomix Enters into Agreement with Noisefigure Research, Inc. to Develop Next Generation of Its Proprietary Microchip	04-25	CI
Autonomix Medical Secures US Patent for Catheter-Based Technology to Treat Cancer-Related Pain	04-16	MT
Autonomix Medical, Inc. Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation	04-09	CI
Autonomix Appoints Jennifer Cook as Chief Business Officer	03-19	CI
Autonomix Medical, Inc.(NasdaqCM:AMIX) added to S&P TMI Index	03-17	CI
Autonomix Medical, Inc. Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market	03-14	CI
Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market	03-06	CI
Autonomix Medical, Inc. Secures Principal Investigators and Completes Clinical Training for First Human Study	02-22	CI
Autonomix Medical, Inc. Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market	02-16	CI
Autonomix Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-13	CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Earnings Overshadow Potential Bond Surge Concerns	02-07	MT
Top Premarket Gainers	02-07	MT
Autonomix Gets Approval to Start Clinical Trial for Pancreatic Cancer Pain Treatment in Uzbekistan	02-06	MT
Autonomix Re-Acquires Sensing Technology from Impulse Medical for $8 Million in Stock	01-30	MT
Autonomix Medical, Inc.(NasdaqCM:AMIX) added to NASDAQ Composite Index	01-30	CI
Autonomix Medical, Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	01-09	CI
Autonomix Medical, Inc. Auditor Raises 'Going Concern' Doubt	06/07/23	CI

Chart Autonomix Medical, Inc.

Duration

Period

More charts

Company Profile

Autonomix Medical, Inc. is a medical device company, which is focused on advancing technologies to treat diseases involving the peripheral nervous system. Its technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate peripheral neural signals with up to 1,000 times sensitivity. It is developing a two-fold technology that can both detect malfunctioning neural signals and ablate nerves in one simple procedure for pain management. It is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation, and chronic pain management across a disease spectrum. Its Autonomix catheter is equipped with a microchip that converts analog signals from the body to a digital signal that can be sent directly to a computer screen.

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
AUTONOMIX MEDICAL, INC.	0.00%	18.09M
THERMO FISHER SCIENTIFIC	+4.18%	211B
DANAHER CORPORATION	+8.00%	185B
INTUITIVE SURGICAL, INC.	+31.86%	158B
BOSTON SCIENTIFIC CORPORATION	+33.21%	113B
SIEMENS HEALTHINEERS AG	+2.28%	64.32B
EDWARDS LIFESCIENCES CORPORATION	+21.14%	55.66B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+0.11%	48.41B
AGILENT TECHNOLOGIES, INC.	-6.76%	37.82B
GE HEALTHCARE TECHNOLOGIES INC.	+0.78%	35.57B

Other Advanced Medical Equipment & Technology